Muiesan G, Fariello R, Muiesan M L, Christensen O E
Eur J Clin Pharmacol. 1985;28(5):495-9. doi: 10.1007/BF00544057.
Pinacidil, a new cyanoguanidine derivative, is an antihypertensive agent with arteriolar vasodilating properties, which acts on precapillary resistance vessels. A trial was carried out in 30 patients with essential hypertension WHO I-II. The treatment period was divided into three phases. Hydrochlorothiazide (HCTZ) and amiloride were administered for 4 weeks in Phase 1 and supine and standing blood pressure decreased significantly. During Phase 2 pinacidil was added to HCTZ/amiloride for the following 3 months. A further significant reduction in blood pressure was obtained. In the next period of treatment (Phase 3) patients were divided into two groups. For 1 month Group A (15 patients) received pinacidil alone and Group B (15 patients) received HCTZ/amiloride. Conventional laboratory blood tests in all patients remained unchanged during treatment. Reported side effects during Phase 2 were headache (2 patients), dizziness (3 patients), palpitations (2 patients) and ankle oedema (2 patients). Plasma renin activity was slightly increased at the end both of Phases 1 and 2. Plasma catecholamines were increased but not significantly at the end of Phase 2 as compared to Phase 1. The results indicate that pinacidil is effective in lowering blood pressure in mild to moderate essential hypertension.
匹那地尔是一种新型的氰基胍衍生物，是一种具有小动脉血管舒张特性的抗高血压药物，作用于毛细血管前阻力血管。对30例世界卫生组织I-II级原发性高血压患者进行了一项试验。治疗期分为三个阶段。第一阶段，氢氯噻嗪（HCTZ）和阿米洛利服用4周，仰卧位和站立位血压显著下降。在第二阶段，接下来的3个月在HCTZ/阿米洛利基础上加用匹那地尔，血压进一步显著降低。在下一治疗阶段（第三阶段），患者被分为两组。1个月内，A组（15例患者）单独服用匹那地尔，B组（15例患者）服用HCTZ/阿米洛利。治疗期间所有患者的常规实验室血液检查结果均未改变。第二阶段报告的副作用有头痛（2例患者）、头晕（3例患者）、心悸（2例患者）和踝部水肿（2例患者）。第一阶段和第二阶段结束时血浆肾素活性均略有升高。与第一阶段相比，第二阶段结束时血浆儿茶酚胺升高但不显著。结果表明，匹那地尔对轻至中度原发性高血压患者降低血压有效。
